Menu
Primary Navigation
–
Pages, Posts & Categories
Home
Posts
Psychedelic websites & blogs
14. October 2022
The role of Indigenous knowledges in psychedelic science
23. January 2022
Ayahuasca & CogPsy
23. January 2022
Psilocybe induced rejuvenation (Reddit)
14. January 2022
Gilgamesh and the Magic Plant
30. December 2021
Ueber Pellote – Ein Beitrag zur pharmakologischen Kenntniss der Cacteen
29. December 2021
Psilocybin study enrolls clinicians with COVID-linked blues
29. December 2021
Predicting Reactions to Psychedelic Drugs: A Systematic Review of States and Traits Related to Acute Drug Effects
26. December 2021
The subjective experience of acute, experimentally-induced Salvia divinorum inebriation
26. December 2021
Identification of a novel member of the family Betaflexiviridae from the hallucinogenic plant Salvia divinorum
26. December 2021
Salvia divinorum: from recreational hallucinogenic use to analgesic and anti-inflammatory action
26. December 2021
Chemical syntheses of the salvinorin chemotype of KOR agonist
26. December 2021
Salvia divinorum increases alcohol intake and tonic immobility whilst decreasing food intake in Wistar rats
26. December 2021
Sociological investigations of human enhancement drugs: The case of microdosing psychedelics
26. December 2021
Tactics of Legitimation in the Psychedelic Sciences: Lessons for Feminist Sociology of Knowledge
26. December 2021
The Effects of Tryptamine Psychedelics in the Brain: A meta-Analysis of Functional and Review of Molecular Imaging Studies
25. December 2021
Schopenhauer on death (Thanatology)
25. December 2021
Arthur Schopenhauer and psychiatry 200 years after the publication of The World as Will and Representation
24. December 2021
A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses
22. December 2021
The Therapeutic Potential of Psilocybin
22. December 2021
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
21. December 2021
5-Methoxy- and 5-Hydroxyindoles in the skin of Bufo alvarius
19. December 2021
Ayahuasca-Tourismus in Peru: Motivationen und subjektive Bedeutungen bei Teilnehmern von Ayahuasca-Retreats im oberen Amazonasgebiet
19. December 2021
The personal experiences of ayahuasca brew users as a therapeutic catalyst for substance dependence: A qualitative exploratory approach
19. December 2021
Exploring the effect of Trichocereus pachanoi on the depression-like behavior in rats
17. December 2021
Mescalina y ritual del cactus de san Pedro: evidencias arqueológicas y etnográficas en el norte de Perú
17. December 2021
Use of Benefit Enhancement Strategies among 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) Users: Associations with Mystical, Challenging, and Enduring Effects
15. December 2021
Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study
15. December 2021
DMT Models the Near-Death Experience
15. December 2021
Neural correlates of the DMT experience assessed with multivariate EEG
15. December 2021
Fractal in HTML & CSS
15. December 2021
Bioactive Components of Salvia and Their Potential Antidiabetic Properties: A Review
15. December 2021
Dark Classics in Chemical Neuroscience: N, N-Dimethyltryptamine (DMT)
14. December 2021
Harnessing psilocybin: Antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice
14. December 2021
Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment
14. December 2021
Tabernanthalog—a water-soluble, non-hallucinogenic, non-toxic analogue of ibogaine
11. December 2021
Newtonian fractal
11. December 2021
A systematic review of psychedelic-assisted psychotherapy for mental health: An evaluation of the current wave of research and suggestions for the future
10. December 2021
Neural Mechanisms and Psychology of Psychedelic Ego Dissolution (Peprint)
10. December 2021
Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention
10. December 2021
The Evolved Psychology of Psychedelic Set and Setting: Inferences Regarding the Roles of Shamanism and Entheogenic Ecopsychology
10. December 2021
Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey
10. December 2021
Recreational use of psychedelics is associated with elevated personality trait openness: Exploration of associations with brain serotonin markers
10. December 2021
5-Hydroxytryptamine and Intestinal Flora on Depressive-Like Behavior Induced by Lead Exposure in Rats
6. December 2021
Serotonin, fearfulness, dominance, and trainability in horses
6. December 2021
Serotonin and cancer
6. December 2021
Serotonin, dopamin and orgasm
6. December 2021
The use of Psilocybin in oncology
3. December 2021
Psilocybin for the treatment of bipolar depression: A review
3. December 2021
Psychedelic (R)Evolution
3. December 2021
Psilocybin induces dendritic spine formation
3. December 2021
Psilocybin & Genetic Ageing
28. November 2021
Slide
Pages
Psychedelics & Shadow-work
Home
Contact
Psychedelic Webdesign
Bitcoin TradingView Widget
Etymology of the term psychedelic
Post with image
Psychedelic companies
JCU
Sir Arthur Eddingtons parabel of the ichthyologist
Psychedelic web-projects
Sir Arthur Eddington: The Philosophy of Physical Science (1938)
Clinical Trails
References 2021
The world is a psychedelic lab (animation)
Clinical trials with psychedelics in 2021
Psilocybin patents
Psilocybin & depression
5-methoxy-N,N-dimethyltryptamine: An ego-dissolving neurochemical catalyst of creativity
Credits
Dataprotection & Legal Disclaimer
Lectures & Presentations
WikiGalaxy
Interactive generative art
Cosmic symbolism
References for psychedelic therapy network
Test DHTML sidebar
Animated Psychedelic-Lab SVG logo
Post overview (list format)
Psychedelics & Fractals
Sitemap
Psychedelic stock watchlist
Psychonautic & Cybernetic
DMT case report (Strassman, 2001)
DMT patents
Psilocybin patent fillings
MDMA patents
Psychedelic Unselfing and Moral Perception (Master thesis)
Psychedelic Collage
Contact form
Meditation – Yoga Nidra
Random Quotes
Neuromodulatory effects of psychedelics: An interactive visual synopsis
Mindmap – Transdisciplinary psychedelic science
Psychedelics and awareness
Psyche & Chronos: Psychedelics and phenomenological time perception
☸️ Mandukya Upanishad
Psychedelics & Cybernetics
Intelligent design
Substances used in project Bluebird, Artichoke, MK-Ultra, and MK-Delta
Putnams “Brain in a vat” (solipsism, naive realism, skepticism and content externalism)
The search for the manchurian candidate
Inner and outer dimensions
Transcending academic and epistemic boundaries: Psychoactive tryptamines and the frontiers of human exploration
Slide
Categories
5-MeO-DMT
Ayahuasca
DMT
Iboga
Media
Mescaline
Psilocybin/Psilocin
Psychdelic Webdesign
Salvia
Varia
Slide
Current location
–
Breadcrumb trail
Path:
Home
/
Clinical trials with psychedelics in 2021
RSS News Feed
–
Dynamically generated updates
Slide
Israel Isn’t a Leader in Psychedelic Healing - It’s an Apartheid State
How I Ease my OCD and Anxiety with Psychedelics
8 Songs for Transformational Psychedelic Mushroom Experiences
How Psychedelic Mushrooms Support Me
MAPS PBC Publishes Results of Successful Confirmatory Phase 3 Trial of MDMA-Assisted Therapy for PTSD
MAPS Launches Online Video Sessions from Psychedelic Science 2023 with The Virtual Trip
FDA Division of Pulmonology, Allergy, and Critical Care Provides Additional Guidance on Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)
FDA Sends the Official Minutes of Type A Meeting for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)
MAPS Receives $5 Million Grant from the Steven & Alexandra Cohen Foundation
MAPS-Sponsored Global Psychedelic Survey Gathers Data for a Crucial View into Psychedelic Use
FDA Grants In-Person Type A Meeting Request to Discuss Clinical Hold on Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)
MAPS Requests FDA for a Type A Meeting to Discuss Clinical Hold for the Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)
Celebrating 37 Years of Psychedelic Science🎉
STATEMENT: MAPS-Funded Phase 3 Research Reports Results from Long-Term Observational Follow-Up Study on MDMA-Assisted Therapy for PTSD
GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression
GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates
GH Research Reports First Quarter 2023 Financial Results and Provides Business Highlights
GH Research Reports Full Year 2022 Financial Results and Provides Business Updates
GH Research Provides Business Updates and Highlights Key Upcoming Milestones
GH Research Reports Third Quarter 2022 Financial Results and Provides Business Updates
GH Research Reports Second Quarter 2022 Financial Results and Provides Business Updates
GH Research Reports First Quarter 2022 Financial Results and Provides Business Updates
GH Research Reports Full Year 2021 Financial Results and Provides Business Updates
GH Research Reports Third Quarter 2021 Financial Results and Provides Business Updates
Slide
Israel Isn’t a Leader in Psychedelic Healing - It’s an Apartheid State
Israel Isn’t a Leader in Psychedelic Healing - It’s an Apartheid State
Publication date: 05-15-2020
Open full article in lightbox
Art by Nikolitsa Paranomos. Image description: Psychedelic blue and white background over the apartheid wall with Palestinian resistance art that reads, “to exist is to resist.” By Amanda GelenderIsrael has recently been featured , heralded as a leader for its investment in psychedelic clinical trials for MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder (PTSD). Israel is the first national government to approve MDMA as part of a “Compassionate Use” program, which allows people to use clinically unproven treatments because their suffering is so severe and unresponsive to available medical interventions. The clinical trials enlist Israelis suffering from PTSD, including Israeli soldiers who have served in the Israeli Defense Forces (IDF). Phase 2 clinical trials for MDMA as a safe and effective treatment for PTSD. Yet when we lean too heavily on the medical model to address mental health challenges, we often miss the root causes of a system of suffering. In this case, the PTSD is not individual pathology or sickness, rather it stems from the ongoingof Palestine.Psychedelics are not and never will be politically neutral: They are rooted in, inextricably tied to and . The use of psychedelics either support or upend the status quo, and the integrity of the psychedelic movement relies on human rights and to always be at the forefront of our work. I agree that everyone deserves healing: PTSD is painful, no matter who experiences it or what the cause is. 18-year old Israelis must serve in the military - they are forced to carry out state violence and clearly the mental health toll is devastatingly high. But
psychedelic healing must first and foremost be a tool to support the freedom of the oppressed - not a balm to soothe those who carry out oppression.
In a , a representative of the Charles and Lynn Schusterman Family Foundation, one of the partners of the MDMA clinical trials, stated: “A society is only as strong as how it cares for its most vulnerable communities. I am proud that Israel is leading the world in exploring new ways to support and treat people suffering from PTSD and psychiatric illnesses. The Compassionate Use program in Israel is an opportunity to
help high-risk populations
[emphasis mine], including IDF soldiers who have served their country, whose mental health needs are often overlooked and underserved [...] over 10% of the Israeli population experiences PTSD, and this figure increases significantly in regions frequented by rocket attacks. Military service is compulsory, and most families in Israel have histories of trauma and persecution.”The “vulnerable community” and “high-risk population” whose “” with “” that is mysteriously absent from the press release, however, are Palestinians. Today is the 72nd anniversary of (meaning “the catastrophe” in Arabic) commemorating the period of time when were dispossessed from their homes to form the state of Israel, more than 450 villages burned. Now in 2020, Palestinians still fight daily for the rights guaranteed to them .Major human rights organizations on the plight of the Palestinians: Israel subjects Palestinians to ongoing persecution that strips their right to personhood, freedom, health, and liberty. Gaza is the site of a and has been called the because in and out of the region, controlling and limiting the supply of , , , and . Israel severely restricts Palestinians’ and subjects them to ,, , , , , and . The has grown to millions of Palestinians - entire generations of families displaced from their homes. Israel enforces , with two very different systems for Jewish and non-Jewish people. I’ll note here that I’m a Jewish American who, like many of my peers, was raised to believe that Israel was a benevolent underdog.If those of us invested in the work of psychedelics ignore the political realities around psychedelic healing, we can become an accomplice to human rights abuses, helping the violent status quo to strengthen and persist. This is another way that the medical model fails us: As long as systems of oppression are firmly in place, there is an endless stream of “patients” seeking medicine to manage something that is much bigger than any one individual. As Jiddu Krishnamurti said, “It's no measure of health to be well adjusted to a profoundly sick society.”It’s also important to follow the money. Israel is deeply invested in becoming an entrepreneurial center of gravity with a booming that includes and businesses. Psychedelic investment by the state of Israel is inextricably tied to its economic interests: An emerging wave of psychedelic and see a tremendous (a for another day) and of course Israel wants to be on the cutting edge. Note that Israel is also of U.S. foreign assistance since World War II, currently receiving about $3.8 billion every year () specifically in military funding. In this way, Israel profits from instigating military violence and it profits from healing the trauma of violence.
They manufacture the illness and the cure.
It’s a compelling open question under what conditions could psychedelics help shift the minds and hearts of people who hoard resources, commit violence, or otherwise uphold oppression. But any project of that nature must be led by those most impacted by injustice, with a political framework that accurately portrays the political reality and power imbalance at play. And it must be accompanied by the understanding that the ultimate goal is to change the systemic conditions that cause suffering, not just to personally feel at peace amidst injustice.This comes at a time when Palestinians call on the world to support their fight to hold Israel accountable to international human rights law. This is the movement and it encompasses everything from to from companies that profit from the Israeli occupation. BDS is a form of non-violent protest notably fighting for freedom from apartheid. There is also a growing movement of allied who speak out and who refuse to serve as soldiers and execute the occupation. When individuals carry out oppression, everyone involved loses their humanity. I say this as a Jewish person who has seen Israel uphold the occupation in my name. It’s devastating to have your community face unspeakable, genocidal suffering only to turn around and become the violent oppressor. And as an American, I know that taxpayer money funds these catastrophic human rights violations. There aren’t enough psychedelics in the world to wash the blood off of our hands.It would be powerful to see commitments from people across the psychedelic field that support the Palestinian people in their struggle for justice. It is vital that psychedelic research teams , , and expand their scope beyond the medical model to really capture the full magnitude of potential psychedelic impact on the global majority. We must always keep our eye on the systemic conditions that cause human suffering because
psychedelics are not meant to heal us back into oppressive systems.
We must apply our psychedelic journeys to birth better worlds. As psychedelics often teach us, our fates are intertwined: Palestinian liberation makes us all more free.
A huge thank you to my creative collaborators Alex Bledsoe and Nikolitsa Paranomos for your support with this piece.
How I Ease my OCD and Anxiety with Psychedelics
How I Ease my OCD and Anxiety with Psychedelics
Publication date: 03-10-2020
Open full article in lightbox
Art by . Image description: Shadow of a person from behind standing on a grass and flower lined path with gold steps in a sea of blue glass overlooking purple mountains and a sunrise. By Amanda GelenderI have struggled with OCD and anxiety for about 25 years. My OCD has shapeshifted over time, camouflaging into each phase of my life, but the themes have remained pretty consistent through the years. At this point in my life, my OCD could perhaps best be described as meaning that while I have compulsions, obsessive and intrusive thought loops are the most debilitating aspects of my condition. At times, OCD fear loops have been so overwhelming that entire parts of my life shut down - for example, I stopped driving for years because I couldn’t shake the terrifying fear that I would accidentally hurt someone.I have been fortunate enough to work with many different healing modalities throughout my life, including talk therapy, community support networks, acupuncture, medications (), cannabis, peer-support group therapy, physical movement, nature, and creative practices. I have also worked extensively with psychedelics to manage my OCD, anxiety, and depression. While I don’t seek or expect a “cure” to my mental health challenges, LSD and psychedelic mushrooms are life changing tools to work through my fears and come to peace with myself, facilitating some of the most transformational healing work of my life.Working with psychedelics to support folks with OCD and anxiety is a topic of deep interest to me both personally and professionally: In addition to my own experiences, my work is to facilitate with psilocybin mushroom truffles. I’m not a doctor or therapist, I facilitate experiences as someone with extensive experience with psychedelics and a love for creating the conditions for others to benefit from them the way I have. Many of the people who reach out for sessions experience anxiety and/or OCD, so I’m frequently in conversation with folks about whether psychedelics may be helpful tools to support them. There are still many open questions about how and why psychedelics impact people the way they do - this is not merely a scientific inquiry, it is also political, philosophical, cultural, and spiritual. In this age of crumbling drug prohibition, western science is trying to catch up to what about the healing potential of entheogenic plant medicine. Researchers have only begun to scratch the surface on psychedelic applications for and , but so far are very promising. I’m confident that in the coming years, psychedelic medicine will become mainstream treatment for a broad range of mental and physical health challenges. We just have to keep our focus on access and , being wary of how these incredibly powerful tools may be and a for-profit medical system.In a neurological context, about classic psychedelics and the brain is that it temporarily quiets down the “default mode network,” a part of the brain that filters and communicates information between various regions. So when the default mode network goes off duty during a psychedelic trip, parts of the brain can communicate that don’t usually talk to each other and new neural connections . We suddenly have unfiltered access to a slew of information, memories, and feelings that are often difficult to tap into in our standard state of consciousness. It can help us feel what some call “ego dissolution,” a sensation that changes , which to the positive benefits of psychedelics. Below is of brain scans depicting the neural connections with psilocybin (image b) and a placebo (image a): Brain scans showing connectivity with psilocybin (right) and with a placebo (left). Credit: Petri et al./Proceedings of the Royal Society Interface But what does this mean on a practical level? Well, it’s different for everyone. I have found that in the psychedelic state it’s easier to go past the mind and work through trauma in my body. I can release control and explore my deepest fears and traumas at the root of my anxieties. I can hold myself with compassion and feel through repressed emotions, tapping into a sense of universal oneness and spiritual connection. I can feel tremendous joy, sorrow, rage, euphoria, and humility, a powerful emotional catharsis that cleans my pipes. In the time after a trip, there is often a window of that can particularly support folks with depression and anxiety - it often feels a bit easier to try new things and shake up old habits. I feel more present and aware of what I want. I feel re-energized, appreciative, and grounded. Ideas, fresh perspectives, and creativity comes more easily. My connections and community work deepens. All of these shifts help ease the daily struggle of anxiety.Of course when we ask a question like, “How can psychedelics help relieve anxiety?” we have to remember the context in which we attempt to heal: Racialized capitalism. We live under political systems that exacerbate and facilitate trauma and perpetual anxiety, particularly for Black and Brown people. It’s very hard to heal yourself in an environment that continues to inflict harm. So we have to remember that while mental health challenges can feel like individual plights, they are often not so much personal pathologies as they are natural ways of responding to our environment. While psychedelics are incredibly powerful tools for exploration and healing, to truly address the roots of mental health crises, our focus must always be on systemic level change.From what I have witnessed with clients, people heal differently with these tools and it can change over time. Some folks have a radical shift after a trip, others may have a more subtle shift or may not resonate with this modality at this point in their life. A trip that facilitates a strong sense of interconnectedness with the universe (ego “death” or dissolution) who struggle with depression and anxiety. But in my experience, ego dissolution isn’t a prerequisite for substantial healing with psychedelics. I like to remind clients that the wisdom from psychedelic sessions can come in many forms: Just because there may not be a stark, immediate shift after a trip doesn’t mean that important work isn’t being done. Rather than a silver bullet, I view psychedelic sessions as powerful steps on a healing and growth path. Each trip I shed another layer and go deeper - it’s a process that can take time. So while my work with psychedelics hasn’t eradicated my OCD or anxiety symptoms, the volume has turned down, and I have renewed mental, emotional, and spiritual fortitude to traverse challenges when they arise. A great example is my writing - OCD would want to block me from publishing this piece (“Have I checked it enough times to see if I said something incorrect? Will I accidentally cause damage with what I share?”...) but I move through the fear and publish anyway. It’s not that those voices aren’t there, it’s that they don’t drive and control my life the way they used to. In working with psychedelics through the years, I’ve become less fear-based. I feel more aligned and at peace with the natural ebb and flow of things.I have also found that psychedelics work well in partnership with other healing modalities. People who have healing practices in place before their trip often have an easier time integrating the lessons from psychedelic journeys. By the same token, psychedelics can enhance existing practices, helping people go deeper and unlock new levels in talk therapy, meditation, and artistic expression, for instance.
Trip Tips for Folks with OCD & Anxiety
The many unknowns of a psychedelic journey can be the perfect catalyst for worry, particularly for those of us with a proclivity towards looping, catastrophizing, and worst-case scenarios. It’s completely normal to be scared before a psychedelic journey - I was certainly terrified before my first psychedelic trip and I’m so grateful to have had thorough preparation and a supportive person there with me to help me feel safe in my exploration.A wide range of experiences are possible in a psychedelic journey and even healing trips can sometimes feel scary or even traumatic. In my experience, going through these dark places in psychedelic journeying can still bring great positivity, but only if the container around the trip is supportive. This is which found that the majority of people who have had challenging psychedelic mushroom experiences still said they were “‘meaningful’ or ‘worthwhile,’ with half of these positive responses claiming it as one of the ” To set yourself up for a safe and transformational session, it’s always wise to follow basic prep guidelines - access the medicine from a trusted and safe source (testing the substance if necessary), know a good starting dose, may affect your trip, prepare and feel as centered as possible before the journey (set), arrange for a safe and nourishing space (setting), have a person with you for support (sitter or guide), and allot time to process in the days following the session (integration). I actually think that a healthy mix of nervousness and excitement before a trip is a good thing: It demonstrates that you have reverence for how powerful a psychedelic teacher is and that it has the potential to significantly shift your life. But of course it’s best not to go into a trip feeling too anxious, so practice grounding yourself before the journey. And if you’re really struggling the days leading up to the trip - don’t push it. Check in with yourself and see if you want to postpone your trip or start with a lower dose. It’s also important to note that psychedelics aren’t for everyone and it can shift depending on what you’re going through. For instance, I don’t go on full dose trips when I am in a depressive crisis, a particularly bad OCD episode, or when I’m very stressed or overworked. I’ve found that these trips can be unnecessarily challenging or even temporarily damaging, so I wait until I feel a bit more stable to have a session. After your trip, be kind to yourself and take time to process in whatever ways feel most natural to you. It can be particularly helpful to write, draw, rest, and be in nature in the days following your journey. It’s normal to feel many things after a trip so let the changes unfold over time and don’t rush to make sense of everything. Be patient if changes don’t come right away and remember that for those of us who struggle with anxiety and OCD, just the act of releasing control and taking the leap into the psychedelic journey is a huge achievement.
8 Songs for Transformational Psychedelic Mushroom Experiences
8 Songs for Transformational Psychedelic Mushroom Experiences
Publication date: 02-27-2020
Open full article in lightbox
Digital drawing of purple, yellow and pink smoke flowing through broad green leaves. Art by Nikolitsa Paranomos.
By
While the impact of music on psychedelic sessions is currently an ongoing , music has been a powerful component of psychedelic journeying for centuries, rooted in indigenous, ceremonial practice with plant medicine. In the context of psychedelic mushroom journeying outside of a shamanistic practice, musical considerations are personal as well as cultural. Not everyone responds well to the most common types of music played in retreat and clinical settings - for instance, clients grappling with the impact of white supremacy on their psyches may be less likely to resonate with classical music that harkens back to colonization. “World” music selected without proper cultural context can miss the mark and feel exoticizing. We need more research focused on experiences of people of color from a wide range of backgrounds to really understand how music can foster breakthroughs in psychedelic sessions.At our in Amsterdam, we support people from many walks of life through legal, sliding-scale, private psychedelic mushroom experiences. Time and again, we’ve witnessed how the right songs played at the right time can facilitate tremendous breakthroughs in psychedelic sessions. We have an individualized approach to music selection: Rather than follow a set playlist, we live-DJ for our clients, pulling from our extensive catalogue of songs to support moment-to-moment flow. We also ask clients to send us music that holds particular significance for them: Peppering in these personal tracks during key moments creates an opportunity to process through emotions, memories, traumas, and relationships.Our individualized approach also means that as guides we are exposed to a steady stream of fresh musical tracks from our clients from around the world. I’ve pulled eight pieces of music from our library that we love to play during client sessions - enjoy! The Come Up
&
- -
The hypnotic, loving music of Beautiful Chorus is a staple for our sessions. Faith’s Hymn and the chakra tracks from their Resonance Meditation album create a soothing, womb-like atmosphere. These songs facilitate a warm, other-worldly invitation into the psychedelic journey. We often play these songs on loop in both the come up and the come down of a session. (Shout out to our collaborator Alex Bledsoe who put us on to their stunning music!)
- -
Radiohead guitarist Jonny Greenwood received an Oscar nomination for his original score for the 2017 film Phantom Thread and this particular track from the film is a go-to for when the trip begins to lift off. The rolling crescendos usher in a fresh, enchanting state of being to set the stage for the journey. The Peak
- -
We love to play this track during the transition from the come-up into the peak of the experience. It’s almost completely instrumental except for the mantra “let it go” spoken as the beat picks up. This song’s layered, hypnotic vibe combined with a powerful mantra of release supports breakthroughs at a time in a trip when surrendering is key.
- -
We were first introduced to Kamasi Washington by a jazz writer client who sent along some of his music for her session. We loved the tracks so much that we incorporated his work into our library. Integrity is hypnotic and layered, definitely worth repeating.
- -
This is a classic track by the legendary Nigerian Afrobeat artist Fela Kuti. It’s an intense, sweeping selection to experience on a psychedelic trip so we save it for the fervency of the peak. We’ve found this song to be a particularly strong choice for Black and Brown clients doing ancestral and work during their session.
- -
This beautiful 2016 track is gentle but rhythmic, invoking the feeling of riding a wave or moving through water. It can play on loop and doesn’t overwhelm the senses, guiding you through a psychedelic state with inspiration and ease. It’s also a wonderful track to create art with on a psychedelic journey. The Come Down
- -
This is one of our favorite songs to loop during the comedown of a psychedelic trip. KOKOROKO is a truly genius Afrobeat collective out of London whose music is at the same time calming and stirring. As clients float back to this plane from their session, the vibes of Abusey Junction are often a welcome homecoming.
-
As the revelations and breakthroughs of a trip are setting in after a full journey, this song brings a loving and poignant presence. It’s a great choice for when folks are coming more fully back into their bodies and can manage a track with lyrics. Nina Simone’s version of this song is a particularly compelling and beautiful choice, given her legacy as a and musical force of nature. We’re always creating new lists and would love to send them directly to you - to catch the vibe.
How Psychedelic Mushrooms Support Me
How Psychedelic Mushrooms Support Me
Publication date: 02-20-2020
Open full article in lightbox
Digital drawing of a blue mushroom with gold strands, circled by pastel painted green leaves. Artist:
By
This piece is my contribution to the #ThankYouPlantMedicine campaign to de-stigmatize and psychedelic plant medicine. From microdosing to full dose experiences, psilocybin “magic” mushrooms have supported me tremendously me over the years. I also work intentionally with cannabis, which continues to bring me healing and positive transformation. For context, I have struggled for many years with several mental health challenges including OCD, depression, and anxiety. I’ve been on prescription medications over the years and am currently on an SSRI . I’m from the Bay Area and live in the Netherlands where psilocybin is legal for purchase in the form of mushroom truffles. I’m the founder of a sliding-scale in Amsterdam - my team and I support people from around the world through psychedelic mushroom truffle sessions with the goal of helping to create a more just, equitable, and sustainable world. Through my own personal transformations and the many client sessions I’ve facilitated, I’ve seen first-hand how with supportive preparation (set) and environment (setting), psychedelic mushrooms have tremendous potential to support people in a multitude of ways (something that indigenous people have ). Learning to work with psychedelics has been an ongoing process: Along with euphoric and joyful moments in trips, I’ve also had very challenging experiences where I was grateful to have a nourishing environment and supportive person at my side. While psychedelics are not for everyone at all points in their lives, they are now a vital part of my wellness and social change work. They also complement and enhance the therapeutic benefits of my other healing modalities. I believe that psychedelic plant medicine, including psilocybin and cannabis, should be and widely accessible for people to grow and share in community. Our focus must always prioritize , , and over - a significant battle under racialized capitalism. But any movement to reduce individual pain has a responsibility to address the systemic causes of suffering. The rise of psychedelic medicine must include to address the generations of damage inflicted on Black and Brown communities through , , and the . The global struggle for indigenous rights is and to all plant medicine practice. I write my story about working with mushrooms in part because my whiteness shields me from impunity - I can speak openly about substance use with less risk than my friends of color. My ability to work with largely illegal medicines as openly as I do and with as little friction as I experience is a direct result of my whiteness - all of the times I have
not
been by police, for instance. I hope our collective stories shared today lead to positive, systemic change. Here are ways psilocybin mushrooms have supported me:
New Ways of Perceiving
In mushroom sessions, I can access fresh perspectives on all facets of life. It can sometimes feel like being given a universal key to explore every room in the house of . I can wander into any space and explore memories, desires, and fears in ways that often feel inaccessible in my standard state of consciousness. Heightened sensations and perceptive shifts in psychedelic sessions allow me to continually gain a deeper understanding of myself and the world around me. This is particularly helpful as someone who frequently experiences anxiety and depressive loops: A new mindset and path forward can mean . Everything I encounter during a psychedelic journey can teach me a lesson, a mindset that also serves me well in daily life. I marvel with profound curiosity and appreciation for everything around me, even if I don’t have language to describe its complexity.
Creative Flow
Mushrooms help me to create without self-censoring. I write and draw freely and unselfconsciously, focused on the joy and power of creating rather than the output. New ideas emerge organically. I deepen my appreciation for music, art, poetry, and natural beauty, as I can perceive these mediums with enhanced meaning and feeling. I gain more forgiveness and understanding for my own creative process, helping me release the shame of not producing “enough” or “better.”
Feel my feelings
Mushrooms help me to feel my feelings with depth and profundity - I often weep, rage, marvel, and burst into uncontrollable laughter. Accessing the entire emotional spectrum helps me to better understand and appreciate my multitudes. The catharsis of full, embodied emotional release on psychedelics has been tremendously healing. Psychedelics help me process through trauma not just cognitively but with my whole being (body, mind, spirit).Psychedelics let me access a well of inner wisdom which gives me a sense of safety, security, and groundedness in my daily life. In working with mushrooms and cannabis over the years, I now feel less resistance to change and more at ease in transition. Even though I have a long way to go in releasing my perfectionism and unnecessary fears,
it’s been a relief to feel more at peace with the natural ebb and flow of things - endings, beginnings, birth, life, death.
Embodiment
Mushrooms help me feel through pain and and programmed into my cells. I can work through and more easily release body shame. I can explore my embodied experience of gender and sexuality. I often experience a resounding, indescribable sense of somatic gratitude which spills into my daily life, relationships, and social change work in the days and weeks to come.
Deepened Connections
After sessions, I often have an enhanced desire for deep connection. I feel more present with myself and others, grateful for the time we have together. I‘m open to new, aligned connections. Because my sessions help me tune into my wants and needs, I feel less fear in sharing my truth and asserting boundaries. After sessions I often initiate uncomfortable conversations that I had been putting off or take the leap to do something I’ve been wanting to do but felt too afraid. I often emerge from trips revitalized, nourished, in deeper connection with those around me, and with a spark of optimism, which feels particularly important and elusive in these bleak political times.
Fuel to Imagine and Build a Better World
We still have a lot to learn about how psychedelics impact and . But I certainly see their radical potential. Mushrooms can help us imagine possibilities outside of dominant paradigms and systems: Tunnels to a better world. Mushrooms let us dissolve boundaries and borders, reminding us that all of our fates are intertwined. They can help us engender deep empathy for all living things, reconnecting us with our roots in the natural world. Psychedelics are not just tools for individual improvement, as asserted by the medical model and dominant neoliberal paradigms. Our collective challenges are systemic and our solutions must be as well. Psychedelics aren’t a substitute for structural change, but they can open us up to new ideas, connect us to our values, and re-energize us to fight for structural solutions, breathing new life into our social change work.As adrienne maree brown, author of , , “Where we are born into privilege, we are charged with dismantling any myth of supremacy. Where we are born into struggle, we are charged with claiming our dignity, joy and liberation.” I think psychedelics can support all sides of this work. For those who experience oppression - particularly Black and Brown folks - psychedelics can be an access point to feel tremendous freedom and healing from generations of racial trauma. They can usher in powerful joy, release, and ancestral connection. They can with the process of , feeling freedom, worth, and truth outside of systems of oppression. And for those with privilege, we can work with psychedelics to explore how to best leverage our resources and positionality for a more just world. Mushrooms can help us all to dream up a better society and then boost our momentum and capacity to actually build that world.
Explore All Things - Mind, Consciousness, Dimensionality, Identity, and Spirituality
Mushrooms give us an opportunity tap into the interconnectedness of all things, the expansiveness of our consciousness, and the energy flow of the universe. They provide direct access to spiritual planes and ancestral wisdom (one the reasons why by indigenous sacred use of mushrooms was unmediated access to the divine). Each trip, mushrooms reveal more data in an unlimited stream of channels, windows, mirrors, and portals. They help to continually pull away at a seemingly endless series of veils, opening access into facets of dimensionality, nonlinear time, and consciousness. Psychedelic exploration will continue to have a tremendous impact on what we know about existence and consciousness.With mushrooms I can deeply explore facets of my queerness, race, sexuality, and gender. I can melt walls I’ve built to shield and protect myself from pain. I can muster the courage to walk into the basement of my subconscious and see what I’ve been too afraid to look at - trauma, guilt, shame, death, failure, abuse, resentment, anxiety, sadness, uncomfortable truths. This work can be painful and exhausting, but it can also be gentle and fortifying. Each session I gain more embodied strategies to accept all parts of myself and traverse life’s challenges. It has been some of the most profound healing work of my life.
MAPS PBC Publishes Results of Successful Confirmatory Phase 3 Trial of MDMA-Assisted Therapy for PTSD
MAPS PBC Publishes Results of Successful Confirmatory Phase 3 Trial of MDMA-Assisted Therapy for PTSD
Publication date: 09-13-2023
Open full article in lightbox
FOR IMMEDIATE RELEASE: September 14, 2023Nature Medicine
has published the peer-reviewed results of MAPP2, the second Phase 3 trial of MDMA-assisted therapy for PTSD
The MAPS-sponsored, philanthropy-funded study met primary and secondary endpoints confirming the first Phase 3 study findings
MAPS PBC expects to file the New Drug Application with the U.S. Food and Drug Administration in 202
3Results of the second, confirmatory Phase 3 trial of MDMA-assisted therapy for posttraumatic stress disorder,
MAPP2,
have been published in
Nature Medicine
.
MAPP2
was sponsored by the (MAPS) and administered by (MAPS PBC), a subsidiary of MAPS. MAPS PBC is compiling data from 18 MAPS-sponsored Phase 2 and Phase 3 studies to form the basis of the New Drug Application, expected to be filed with the FDA later this year. Thanks to the combined efforts of dozens of therapists, hundreds of participants who volunteered in MAPS-sponsored trials, and many thousands of generous donors, MDMA-assisted therapy for PTSD is on track to be considered for approval by the FDA in 2024.
Nature Medicine
has published the results of the second MAPS-sponsored Phase 3 trial of MDMA-assisted therapy for PTSD, confirming our prior results. We hope that MDMA-assisted therapy for PTSD will be approved by the FDA next year — and that our Open Science, Open Books principle will inspire researchers to make this just the first of many psychedelic-assisted therapies to be validated through diligent research.
, MAPS Founder and President
Keep Reading… ###
NOTE
The safety and efficacy of all psychedelic-assisted therapies, including MDMA-assisted therapy, are currently under investigation. No psychedelic-assisted therapy has been approved by the FDA or other regulatory authorities; no therapy works for everyone; and all therapies, even in clinical settings, carry risks.
ABOUT
Founded in 1986, MAPS is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS is sponsoring the most advanced psychedelic therapy research in the world through its wholly-owned subsidiaries and . Since MAPS was founded, philanthropic donors and grantors have given more than $140 million for psychedelic and marijuana research and education. MAPS has earned both the and a.The post
MAPS PBC Publishes Results of Successful Confirmatory Phase 3 Trial of MDMA-Assisted Therapy for PTSD
appeared first on
Multidisciplinary Association for Psychedelic Studies - MAPS
.
MAPS Launches Online Video Sessions from Psychedelic Science 2023 with The Virtual Trip
MAPS Launches Online Video Sessions from Psychedelic Science 2023 with The Virtual Trip
Publication date: 08-30-2023
Open full article in lightbox
PS2023: The Virtual Trip offers an opportunity to access a wide spectrum of sessions from Psychedelic Science 2023, the largest psychedelics conference in history.
With a rolling release schedule, nearly 300 recorded sessions will become available over the coming months.
Operating under a pay-what-you-can model, MAPS ensures that financial constraints do not hinder anyone’s ability to access this transformative content.
The (MAPS) has begun publishing a collection of content from the highly acclaimed Psychedelic Science 2023 conference. brings the world’s leading experts in psychedelic research, therapies, policy, culture, and business to the general public through an affordable and accessible online platform.
Set the Setting,
the first compilation of videos from the June 2023 conference, highlights a diverse range of sessions encompassing the medical, mystical, marginalized, and mainstream aspects of the psychedelic ecosystem. PS2023: The Virtual Trip is a MAPS initiative to provide access to nearly all recorded sessions from the in-person conference held in Denver, CO this year. Set to unfold in a rolling release throughout the fall of 2023, this collection offers attendees and enthusiasts the chance to relive their favorite moments, catch up on missed sessions from psychedelic experts, and partake in an unparalleled journey of knowledge and insight.The Virtual Trip is an invitation to anyone interested in learning more about psychedelics. It’s not just a collection of speaker sessions and panels; it’s a portal to exploration, understanding, and connection. With ‘Set the Setting,’ our curated introduction, anyone can engage with the transformative experience of Psychedelic Science sessions, set their learning intentions, and embrace the journey that lies ahead. At MAPS, we believe that knowledge knows no boundaries, and through our ‘pay what you can’ approach, we’re excited to foster a sense of inclusivity that reflects the core values of our organization.
, Director of Communications, MAPS
The content and learnings within this collection offer a chance for patients, therapists, investors, and all other stakeholders within the industry to become immersed in the invaluable knowledge-sharing and community spirit that defined the conference. Access to the content follows a pay-what-you-can model enabling everyone to access this transformative content. By fostering an environment of reciprocity, MAPS aims to ensure that financial constraints do not hinder the pursuit of knowledge. A detailed explanation of the suggested contribution model can be found .The Virtual Trip is what I’ve been waiting for all summer! It’s a treasure trove for anyone who attended the Psychedelic Science 2023 conference. It’s a chance to relive those thought-provoking talks, captivating presentations, and moments of connection that made the conference so special. I can’t wait to dive back into the sessions I loved and explore the ones I missed. I’m excited to be part of this Virtual Trip into the world of Psychedelic Science 2023 once again.
Psychedelic Science Attendee
PS2023: The Virtual Trip is now available at .
ABOUT
Founded in 1986, MAPS is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS is sponsoring the most advanced psychedelic therapy research in the world through its subsidiary . Since MAPS was founded, philanthropic donors and grantors have given more than $140 million for psychedelic and marijuana research and education. MAPS has earned both the and a.The post
MAPS Launches Online Video Sessions from Psychedelic Science 2023 with The Virtual Trip
appeared first on
Multidisciplinary Association for Psychedelic Studies - MAPS
.
FDA Division of Pulmonology, Allergy, and Critical Care Provides Additional Guidance on Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)
FDA Division of Pulmonology, Allergy, and Critical Care Provides Additional Guidance on Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)
Publication date: 08-11-2023
Open full article in lightbox
On August 11, the FDA Division of Pulmonology, Allergy, and Critical Care (DPACC) sent MAPS additional guidance on the safety of smoking in naïve subjects in MJP2. The FDA’s correspondence was a follow-up response after the Type A meeting, which was held on June 15, 2023. As the DPACC team was not in attendance at the Type A meeting, many key questions regarding the administration methods were not able to be addressed in the meeting. As a follow-up, to DPACC to include in post-meeting comments for the meeting. The initial on July 12 indicated that “The Division of Pulmonology, Allergy and Critical Care (DPACC) will provide additional guidance in a separate post-meeting communication to help the Sponsor select the most appropriate method.” Unfortunately, the DPACC’s advice misunderstood MAPS’s proposed vaporization protocol. MAPS proposed dried cannabis flower vaporization, while the comments from DPACC were in response to a materially different administration method: the vaporization of isolated cannabinoids in oil delivered through a vape pen.MAPS received the additional comments and on August 11, which can be read here.
2023.08.11 – IND 110513 MJP2 Advice (DPACC Comments)_Redacted
The post
FDA Division of Pulmonology, Allergy, and Critical Care Provides Additional Guidance on Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)
appeared first on
Multidisciplinary Association for Psychedelic Studies - MAPS
.
FDA Sends the Official Minutes of Type A Meeting for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)
FDA Sends the Official Minutes of Type A Meeting for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)
Publication date: 07-12-2023
Open full article in lightbox
On July 12, 2023, the FDA Division of Psychiatry sent MAPS the official minutes of our on June 15, 2023. The Type A meeting focused on the issues the FDA cited in its Clinical Hold on the MJP2 study protocol. MAPS and the FDA discussed strategies to resolve the cited issues so the study can move forward. The FDA has not yet submitted the comments from its pulmonary team, which the FDA project manager indicated MAPS would receive before the end of July. MAPS’ next step is to submit a revised protocol.
IND 110513 MJP2 Type A Meeting Minutes_260712_Redacted
The post
FDA Sends the Official Minutes of Type A Meeting for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)
appeared first on
Multidisciplinary Association for Psychedelic Studies - MAPS
.
MAPS Receives $5 Million Grant from the Steven & Alexandra Cohen Foundation
MAPS Receives $5 Million Grant from the Steven & Alexandra Cohen Foundation
Publication date: 06-22-2023
Open full article in lightbox
MAPS and the Steven & Alexandra Cohen Foundation Partner to Support the Development of Psychedelic-Assisted Therapies
FOR IMMEDIATE RELEASE:
June 22, 2023The (MAPS) today announced that the has awarded MAPS a $5 million grant. The grant provides MAPS with vital mission support as it enters the final stages of the drug development process for MDMA-assisted therapy for the treatment of PTSD. (MAPS PBC), a MAPS subsidiary, plans to submit the New Drug Application for MDMA-assisted therapy for PTSD to the FDA later this year. If the treatment is approved by the FDA, advocates and companies will work to integrate approved therapy into the healthcare system. However, not unlike many other mental healthcare treatments and therapies, those who are prescribed the treatment and are without insurance coverage, or the means to pay out-of-pocket costs, may face financial burdens to access the therapy.This innovative grant not only supports MAPS’ mission today, but also will establish the foundation of a financial assistance program for patients if MDMA- and other psychedelic-assisted therapies are approved by the FDA.Millions of Americans, including our veterans and first responders, suffer from PTSD and other mental health conditions that affect their quality of life. Psychedelic compounds represent a new opportunity to address these often treatment-resistant conditions and bring hope to patients.
, President, Steven & Alexandra Cohen Foundation
The Steven & Alexandra Cohen Foundation’s philanthropic support of MAPS, and clinical research, exemplifies the Foundation’s commitment to patient access. The Steven & Alexandra Cohen Foundation and MAPS have a shared commitment to ensuring there is equitable access to MDMA- and other psychedelic-assisted therapies.We extend tremendous gratitude to the Steven & Alexandra Cohen Foundation for their unwavering support in helping us bring MDMA-assisted therapy through the pipeline and toward potential FDA approval. Our hearts are uplifted by their commitment to equitable access— a crucial element for us to try to bring healing for all.
, PhD, Founder and President, MAPS
The Steven & Alexandra Cohen Foundation’s Cohen Psychedelic Research & Health Initiative is one of the largest private funders of research into psychedelics for debilitating and chronic mental health conditions, including addiction, anxiety, and major depression, with over $60 million of grant commitments to psychedelics. Since 2020, the Steven & Alexandra Cohen Foundation has committed over $10 million of philanthropic support to MAPS’ mission, including MAPS-sponsored clinical research of MDMA- assisted therapy.
NOTE
The safety and efficacy of psychedelic-assisted therapies are currently under investigation. No psychedelic-assisted therapy has been approved by the FDA or other regulatory authorities; no therapy works for everyone; and all therapies, even in clinical settings, carry risks. MDMA-assisted therapy has not been approved by any regulatory agency. The safety and efficacy of MDMA-assisted therapy have not been established for the treatment of PTSD.
ABOUT
Founded in 1986, MAPS is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS is sponsoring the most advanced psychedelic therapy research in the world through its subsidiary . Since MAPS was founded, philanthropic donors and grantors have given more than $140 million for psychedelic and marijuana research and education. MAPS has earned both the and a.
ABOUT
The Steven & Alexandra Cohen Foundation is committed to inspiring philanthropy and community service by creating awareness, offering guidance, and leading by example to show the world what giving can do. The Foundation’s grants support nonprofit organizations based in the United States that either help people in need or solve complex problems. The Foundation also spearheads grassroots campaigns to encourage others to give. For more information, visit .The post
MAPS Receives $5 Million Grant from the Steven & Alexandra Cohen Foundation
appeared first on
Multidisciplinary Association for Psychedelic Studies - MAPS
.
MAPS-Sponsored Global Psychedelic Survey Gathers Data for a Crucial View into Psychedelic Use
MAPS-Sponsored Global Psychedelic Survey Gathers Data for a Crucial View into Psychedelic Use
Publication date: 05-22-2023
Open full article in lightbox
FOR IMMEDIATE RELEASE: May 22, 2023
The (MAPS) announced the launch of the . Co-sponsored by MAPS, SABI Mind, Mind Medicine Australia, and Tiny, the survey marks the most comprehensive assessment of psychedelic use amongst adults to date. In keeping with the spirit of community-based research and harm reduction, the Global Psychedelic Survey provides English-speaking adults from around the globe the opportunity to share their experiences, expertise, and opinions via a general population survey of psychedelic use. The 2023 Global Psychedelic Survey will provide policymakers, researchers, and advocates with a better understanding of international psychedelic use and associated impacts on physical and psychological health through direct reporting from as many as 5,000 people who use psychedelics.The information gathered may be published in academic journals and presented at scientific conferences and other public meetings. Data will be anonymously collected from English-speaking adults from across the globe. will be available online from May 19th through June 2nd, 2023. The Global Psychedelic Survey will give us crucial information about how most people consume psychedelics, which is outside of clinical research and the medical system. This is a great way for us to learn from people’s lived experiences and make evidence-based decisions.
, Founder and President, MAPS
While all submissions are completely anonymous, participants will have an opportunity to be entered into a drawing for one of three $500 USD Amazon gift certificates by providing their email address at the end of the survey.
Contact:
media@maps.org###
ABOUT
Founded in 1986, MAPS is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS is sponsoring the most advanced psychedelic therapy research in the world through its wholly-owned subsidiaries and . Since MAPS was founded, philanthropic donors and grantors have given more than $140 million for psychedelic and marijuana research and education. MAPS has earned both the and a.The post
MAPS-Sponsored Global Psychedelic Survey Gathers Data for a Crucial View into Psychedelic Use
appeared first on
Multidisciplinary Association for Psychedelic Studies - MAPS
.
FDA Grants In-Person Type A Meeting Request to Discuss Clinical Hold on Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)
FDA Grants In-Person Type A Meeting Request to Discuss Clinical Hold on Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)
Publication date: 05-09-2023
Open full article in lightbox
After reviewing MAPS’ Type A Meeting Request and Briefing submitted on April 28, the FDA granted MAPS’ meeting request. MAPS and the FDA will have a face-to-face formal meeting to discuss the Clinical Hold for Study MJP2 in order to gain agreement on the sufficiency of the safety information to support the proposed dosing paradigm, proposed administration instructions, and inclusion of cannabis-naïve participants. While the FDA has limited availability for face-to-face meetings, the Agency has determined that this meeting falls into one of the prioritized meeting types and granted the request for an in-person meeting. This Type A meeting will take place on June 15, 2023, at the FDA Headquarters in Silverspring, MD. .
MJP2 Type A Meeting Request Granted 09May2023_Redacted
The post
FDA Grants In-Person Type A Meeting Request to Discuss Clinical Hold on Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)
appeared first on
Multidisciplinary Association for Psychedelic Studies - MAPS
.
MAPS Requests FDA for a Type A Meeting to Discuss Clinical Hold for the Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)
MAPS Requests FDA for a Type A Meeting to Discuss Clinical Hold for the Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)
Publication date: 04-28-2023
Open full article in lightbox
On April 28, 2023, MAPS requested the FDA for a Type A meeting to discuss the clinical hold issues for Study MJP2 in order to overcome the clinical hold deficiencies. This meeting request is in response to the Agency’s recommendation for a meeting noted in the Partial Clinical Hold Letter dated December 16, 2022. The objective of this meeting is to gain agreement from the Agency on the sufficiency of the safety information to support the proposed dosing paradigm, proposed administration instructions, and inclusion of cannabis-naïve participants. .
MJP2 Type A Meeting Briefing 20APR2023
The post
MAPS Requests FDA for a Type A Meeting to Discuss Clinical Hold for the Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)
appeared first on
Multidisciplinary Association for Psychedelic Studies - MAPS
.
Celebrating 37 Years of Psychedelic Science🎉
Celebrating 37 Years of Psychedelic Science🎉
Publication date: 04-08-2023
Open full article in lightbox
“You and I are the force for transformation in the world. We are the consciousness that will define the nature of the reality we are moving into.”
Today is MAPS’ 37th anniversary! Almost 4 decades ago, Rick Doblin, Ph.D., (or as we call him, Ricky D), founded the Multidisciplinary Association for Psychedelic Studies (MAPS) to develop medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. The
psychedelic brick road
that MAPS donors, employees, and volunteers has paved for the psychedelic space is nothing shy of miraculous. What started as a vision, idea, and dream shared by just a few people has now grown into a movement across the globe. As one of MAPS’ newest employees, it’s an honor to be writing this note in celebration of MAPS
and
the individuals who have supported MAPS’ mission for 37+ years. It wasn’t too long ago that I was supporting MAPS from afar through donations, educating friends and family members on psychedelics, and advocating for MAPS’ mission. Although you may not work directly for or with the organization (yet ), your support is key and helps steer this psychedelic ship forward. MAPS wouldn’t be what it is or where it is today without
you
. So on behalf of everyone here, thank you! If you’re wondering how the MAPS team plans to celebrate our 37th anniversary, it’s all together in community at in June, and we hope to see you there!“Psychedelic Science 2023 will be a bridge connecting the medical, the mystical, the marginalized, and the mainstream as we move together toward mass mental health.”
, MAPS Founder and President
As MAPS rolls into its 38th year, we’re excited to continue moving toward expanded mental health treatments, psychedelic policy change, and working together , with you, to create evidence–based pathways to psychedelics. With love,P.S. Next year, MAPS’ 38th anniversary coincides with the . It’ll be a cosmic celebration, so save the date! P.P.S. In honor of our anniversary, help MAPS continue our longevity and fulfill our mission by .The post
Celebrating 37 Years of Psychedelic Science🎉
appeared first on
Multidisciplinary Association for Psychedelic Studies - MAPS
.
STATEMENT: MAPS-Funded Phase 3 Research Reports Results from Long-Term Observational Follow-Up Study on MDMA-Assisted Therapy for PTSD
STATEMENT: MAPS-Funded Phase 3 Research Reports Results from Long-Term Observational Follow-Up Study on MDMA-Assisted Therapy for PTSD
Publication date: 04-05-2023
Open full article in lightbox
FOR IMMEDIATE RELEASE: April 5, 2023
Interim results show improvements in PTSD symptom severity lasted at least six months after the last treatment session
MAPS Public Benefit Corporation (), a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (), announced preliminary findings from the observational study Long-Term Safety and Persistence of Effectiveness of Manualized MDMA-Assisted Therapy for the Treatment of Posttraumatic Stress Disorder (). According to MAPS PBC, these preliminary findings “show that participants in this study demonstrated a durable response at least six months, and in some cases a year or more, after their final MDMA-assisted therapy session during the Phase 3 study.” The first long-term observational follow-up analysis of six pooled phase 2 trials, , demonstrated that the treatment effects were sustained for at least one year following the treatment sessions. MDMA-assisted therapy is initially intensive — for both participants and practitioners — because it’s a process that seeks to treat root causes rather than just minimize symptoms. While patients and practitioners need to know the treatment effects could be long-lasting to invest their time, insurers need to understand the same to provide coverage. The results of this follow-up study suggest the durability of treatment results and the financial viability of MDMA-assisted therapy for PTSD.
, Founder and President, MAPS
Keep Reading… ###
NOTE
The safety and efficacy of psychedelic-assisted therapies are currently under investigation. No psychedelic-assisted therapy has been approved by the FDA or other regulatory authorities; no therapy works for everyone; and all therapies, even in clinical settings, carry risks.
ABOUT
Founded in 1986, MAPS is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS is sponsoring the most advanced psychedelic therapy research in the world through its wholly-owned subsidiaries and . Since MAPS was founded, philanthropic donors and grantors have given more than $145 million for psychedelic and marijuana research and education. MAPS has earned both the and a.The post
STATEMENT: MAPS-Funded Phase 3 Research Reports Results from Long-Term Observational Follow-Up Study on MDMA-Assisted Therapy for PTSD
appeared first on
Multidisciplinary Association for Psychedelic Studies - MAPS
.
GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression
GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression
Publication date: 09-29-2023
Open full article in lightbox
GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates
GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates
Publication date: 08-23-2023
Open full article in lightbox
GH Research Reports First Quarter 2023 Financial Results and Provides Business Highlights
GH Research Reports First Quarter 2023 Financial Results and Provides Business Highlights
Publication date: 05-11-2023
Open full article in lightbox
GH Research Reports Full Year 2022 Financial Results and Provides Business Updates
GH Research Reports Full Year 2022 Financial Results and Provides Business Updates
Publication date: 03-02-2023
Open full article in lightbox
GH Research Provides Business Updates and Highlights Key Upcoming Milestones
GH Research Provides Business Updates and Highlights Key Upcoming Milestones
Publication date: 01-09-2023
Open full article in lightbox
GH Research Reports Third Quarter 2022 Financial Results and Provides Business Updates
GH Research Reports Third Quarter 2022 Financial Results and Provides Business Updates
Publication date: 11-10-2022
Open full article in lightbox
GH Research Reports Second Quarter 2022 Financial Results and Provides Business Updates
GH Research Reports Second Quarter 2022 Financial Results and Provides Business Updates
Publication date: 08-23-2022
Open full article in lightbox
GH Research Reports First Quarter 2022 Financial Results and Provides Business Updates
GH Research Reports First Quarter 2022 Financial Results and Provides Business Updates
Publication date: 05-18-2022
Open full article in lightbox
GH Research Reports Full Year 2021 Financial Results and Provides Business Updates
GH Research Reports Full Year 2021 Financial Results and Provides Business Updates
Publication date: 03-28-2022
Open full article in lightbox
GH Research Reports Third Quarter 2021 Financial Results and Provides Business Updates
GH Research Reports Third Quarter 2021 Financial Results and Provides Business Updates
Publication date: 12-06-2021
Open full article in lightbox
Latest Publications
–
Scientific literature 2020/2021
pulls refs test
References 2021
Importing BibTeX data...
0%
Contact
–
Get in touch…
pulls refs test
Get in touch...
Contact Dr. Christopher B. Germann
transmissions@psychedelic-lab.com
Your name
Your email
Subject
Your message
Please prove you are human by selecting the
Star
.
Δ
Open form in lightbox window
Search
–
Intelligent search function
Intelligent Boolenan Search function (auto-completion)
Generic selectors
Exact matches only
Exact matches only
Search in title
Search in title
Search in content
Search in content
Search in excerpt
Search in posts
Search in posts
Search in pages
Search in pages
Search in posts
Search in posts
Search in pages
Search in pages
Search in posts
Search in posts
Search in pages
Search in pages
trials 2021
Top